Thanks Ma420. Its a great interview, and AT expands on the additional pre-clinical work that looks at other indications beyond prostate cancer.
Clearly Clarity is developing a substantial platform that into the future will be huge. I can see the Company, if it were to survive as a separate entity, to be a leader in cancer diagnostics and therapy over a broader spectrum than the current market can possibly value.
It really is an exciting pioneer in the radiopharma space and AT is an impressive leader.
Thanks Ma420. Its a great interview, and AT expands on the...
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.78 |
Change
0.270(4.15%) |
Mkt cap ! $2.169B | |||
| Open | High | Low | Value | Volume |
| $6.63 | $6.88 | $6.60 | $11.91M | 1.752M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1600 | $6.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.80 | 2400 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |